Kalaris Therapeutics
KLRS
90 hedge funds and large institutions have $115M invested in Kalaris Therapeutics in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 20 reducing their positions, and 18 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 20
0.02% less ownership
Funds ownership: 2.07% → 2.05% (-0.02%)
4% less funds holding
Funds holding: 94 → 90 (-4)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
37% less capital invested
Capital invested by funds: $184M → $115M (-$68.1M)
42% less call options, than puts
Call options by funds: $59K | Put options by funds: $102K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.57M |
| 2 |
BlackRock
New York
|
+$1.54M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1M |
| 4 |
Morgan Stanley
New York
|
+$833K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$758K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$2.5M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.36M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.27M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.04M |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$994K |
KLRS Hedge Fund Activity: Q3 2023 in Review
90 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2023, worth a combined $115M — down 37% from $184M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of KLRS and 14 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 40 added.
The largest buyer was Millennium Management, adding an estimated $1.57M. The largest seller was Maven Securities, exiting entirely with an estimated $2.5M sold.
- 90 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2023, down from 94 in Q2 2023.
- Funds reported $115M of Kalaris Therapeutics stock for Q3 2023, down 37% quarter-over-quarter.
- 14 funds opened new Kalaris Therapeutics positions in Q3 2023 and 18 closed out, a net change of -4 holders.
- The largest Kalaris Therapeutics buyer in Q3 2023 was Millennium Management, an estimated $1.57M added.
- The largest Kalaris Therapeutics seller in Q3 2023 was Maven Securities, an estimated $2.5M sold.
Based on aggregated 13F filings for Q3 2023.